8F8 Stock Chart & Stats
€2.08
€0.06(6.50%)
At close: 4:00 PM EST
€2.08
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€0.97 - €2.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€85.59M
Enterprise Value€1.17B
Total Cash (Recent Filing)€14.23M
Total Debt (Recent Filing)€929.00K
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding56,213,966
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low leverage reduces fixed financial obligations and preserves flexibility while SynAct funds clinical development. Compared with a highly indebted biotechnology company, this structure lowers balance-sheet stress and leaves fewer creditor claims competing with resources needed for research and pipeline advancement.
Differentiated Clinical ApproachSynAct’s focus on resolving inflammation rather than broadly suppressing the immune system provides a potentially differentiated therapeutic proposition. Its oral lead candidate and evaluation across inflammatory and autoimmune conditions create a defined platform for clinical value creation if development results support the intended profile.
Substantial Equity BaseA sizable equity base relative to total assets provides a meaningful balance-sheet foundation for a clinical-stage company. Although it does not remove the need for future financing, the current capital structure offers more resilience for continuing development than one dominated by debt or limited shareholder capital.
Bears Say
No Commercial RevenueThe absence of commercial revenue means SynAct has no established operating inflow to fund research, trials, or corporate costs. Near-term financial progress therefore depends on clinical advancement and eventual partnering or commercialization, making the business model inherently dependent on future pipeline monetization.
Sustained Cash BurnPersistently negative operating and free cash flow shows that current activities consume capital rather than generate it. Continued clinical development will therefore require careful cash management and likely external funding, which can constrain strategic flexibility and create dilution risk for existing shareholders.
Heavy, Uneven LossesLarge recurring operating and net losses, together with an uneven cost trajectory, indicate that SynAct has not yet demonstrated scalable economics. The negative return on equity and renewed deterioration from earlier periods reinforce the risk that spending remains high before the pipeline can support sustainable profitability.
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.97 and its highest was €2.23 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €85.59M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Nov 03, 2026 which is in 17 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Aug 20, 2026. The company reported -€0.035 earnings per share for the quarter.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 56,213,966 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.035 in its last earnings report. Following the earnings report the stock price went down -11.574%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
InDex Pharmaceuticals Holding AB
―
Active Biotech AB
―
Cantargia AB
―